Table 2.

Mesenchymal Stem Cells Injection Reduces Kidney Donor-Specific Antibody Levels

	% F344 DSA-I
	12 weeks	24 weeks	P
NT	54.3±19.9	86.1±2.284	0.043
BMC	65.8±13.5	46.8±15.5a	NS
MSC	16.1±5.25b	35.1±15.9a	NS

	% F344 DSA-II
	12 weeks	24 weeks	P
NT	8.87±4.9	31.6±5.2	0.03
BMC	22.4±6.6	17.1±6.1	NS
MSC	1.6±1.2b	15.5±7.1c	NS

The presence of circulating DSA class-I and class-II was quantified on recipient serum samples incubated with kidney donor (F344) spleen cells and measured by flow cytometry. A fluorescence increase of 15% with regard to the negative control was considered positive. Results were expressed as a percentage of positive cells with regard to the total number of CD3⁺ spleen cells. DSA titters were analyzed by analysis of variance followed by Scheffe's test. MSC treatment protects from developing DSAs from 1 week after the injection (12 weeks) and at 24 weeks. The BMCs injection has a different reaction, increasing the DSAs at 1 week after cell transplantation and maintaining them along with time.

^aP≤0.04 versus NT, ^bP=0.06 versus BMC; ^cP=0.06 versus NT.

DSAs, donor specific antibodies.